Efficient production of erythroid, megakaryocytic and myeloid cells, using single cell-derived iPSC colony differentiation

Stem Cell Res. 2018 May:29:232-244. doi: 10.1016/j.scr.2018.04.016. Epub 2018 Apr 28.

Abstract

Hematopoietic differentiation of human induced pluripotent stem cells (iPSCs) provide opportunities not only for fundamental research and disease modelling/drug testing but also for large-scale production of blood effector cells for future clinical application. Although there are multiple ways to differentiate human iPSCs towards hematopoietic lineages, there is a need to develop reproducible and robust protocols. Here we introduce an efficient way to produce three major blood cell types using a standardized differentiation protocol that starts with a single hematopoietic initiation step. This system is feeder-free, avoids EB-formation, starts with a hematopoietic initiation step based on a novel single cell-derived iPSC colony differentiation and produces multi-potential progenitors within 8-10 days. Followed by lineage-specific growth factor supplementation these cells can be matured into well characterized erythroid, megakaryocytic and myeloid cells with high-purity, without transcription factor overexpression or any kind of pre-purification step. This standardized differentiation system provides a simple platform to produce specific blood cells in a reproducible manner for hematopoietic development studies, disease modelling, drug testing and the potential for future therapeutic applications.

Keywords: Differentiation; Erythroid; Hematopoietic; Megakaryocytic; Myeloid; iPSC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Culture Techniques*
  • Cell Differentiation*
  • Erythroid Cells* / cytology
  • Erythroid Cells* / metabolism
  • Humans
  • Induced Pluripotent Stem Cells* / cytology
  • Induced Pluripotent Stem Cells* / metabolism
  • Megakaryocytes* / cytology
  • Megakaryocytes* / metabolism
  • Myeloid Cells* / cytology
  • Myeloid Cells* / metabolism